<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37522243</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Paxlovid reduces the risk of Long COVID in patients six months after hospital discharge.</ArticleTitle><Pagination><StartPage>e29014</StartPage><MedlinePgn>e29014</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29014</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Danyang</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Wenying</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Rongyu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Shanghai University of Medicine &amp; Health Sciences Affiliated Zhoupu Hospital, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xubo</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, Shidong Hospital, Yangpu District, Shidong Hospital affiliated to University of Shanghai for Science and Technology, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Liuliu</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-6811-5646</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000719967">nirmatrelvir and ritonavir drug combination</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010351" MajorTopicYN="N">Patient Discharge</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>5</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37522243</ArticleId><ArticleId IdType="doi">10.1002/jmv.29014</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Ayoubkhani D, Bosworth ML, King S, et al. Risk of Long Covid in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study. Paper presented at: Open Forum Infectious Diseases, 2022.</Citation></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nature Med. 2021;27(4):626-631.</Citation></Reference><Reference><Citation>Menges D, Ballouz T, Anagnostopoulos A, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: a population-based cohort study. PLoS One. 2021;16(7):e0254523.</Citation></Reference><Reference><Citation>Montani D, Savale L, Noel N, et al. Post-acute COVID-19 syndrome. Eur Respir Rev. 2022;31(163):210185.</Citation></Reference><Reference><Citation>Tleyjeh IM, Saddik B, AlSwaidan N, et al. Prevalence and predictors of post-acute COVID-19 syndrome (PACS) after hospital discharge: a cohort study with 4 months median follow-up. PLoS One. 2021;16(12):e0260568.</Citation></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health - Eur. 2021;6:100122.</Citation></Reference><Reference><Citation>Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023;76(3):e342-e349.</Citation></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for High-Risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397-1408.</Citation></Reference><Reference><Citation>Loosen SH, Jensen BEO, Tanislav C, Luedde T, Roderburg C, Kostev K. Obesity and lipid metabolism disorders determine the risk for development of long COVID syndrome: a cross-sectional study from 50,402 COVID-19 patients. Infection. 2022;50(5):1165-1170.</Citation></Reference><Reference><Citation>Lapa J, Rosa D, Mendes JPL, Deusdar&#xe1; R, Romero GAS. Prevalence and associated factors of post-COVID-19 syndrome in a Brazilian cohort after 3 and 6 months of hospital discharge. Int J Environ Res Public Health. 2023;20(1):848.</Citation></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259-264.</Citation></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nature Med. 2022;28(7):1461-1467.</Citation></Reference><Reference><Citation>Fang X, Ming C, Cen Y, et al. Post-sequelae one year after hospital discharge among older COVID-19 patients: a multi-center prospective cohort study. J Infect. 2022;84(2):179-186.</Citation></Reference><Reference><Citation>Daugherty SE, Guo Y, Heath K, et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021;373:n1098.</Citation></Reference><Reference><Citation>Boglione L, Meli G, Poletti F, et al. Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? QJM. 2022;114(12):865-871.</Citation></Reference><Reference><Citation>Daynes E, Gerlis C, Briggs-Price S, Jones P, Singh SJ. COPD assessment test for the evaluation of COVID-19 symptoms. Thorax. 2021;76(2):185-187.</Citation></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-232.</Citation></Reference><Reference><Citation>Wong MCS, Huang J, Wong YY, et al. Epidemiology, symptomatology, and risk factors for long COVID symptoms: population-Based, multicenter study. JMIR Public Health Surveill. 2023;9:e42315.</Citation></Reference><Reference><Citation>Yip TCF, Lui GCY, Lai MSM, et al. Impact of the use of oral antiviral agents on the risk of hospitalization in community coronavirus disease 2019 patients (COVID-19). Clin Infect Dis. 2023;76(3):e26-e33.</Citation></Reference><Reference><Citation>Ma BHM, Yip TCF, Lui GCY, et al. Clinical outcomes following treatment for COVID-19 with Nirmatrelvir/Ritonavir and molnupiravir among patients living in nursing homes. JAMA Netwk Open. 2023;6(4):e2310887.</Citation></Reference><Reference><Citation>Tian F, Chen Z, Feng Q. Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: a systematic review and meta-analysis. J Med Virol. 2023;95(4):e28732.</Citation></Reference><Reference><Citation>Wang Y, Chen X, Xiao W, Zhao D, Feng L. Rapid COVID-19 rebound in a severe COVID-19 patient during 20-day course of Paxlovid. J Infect. 2022;85(5):e134-e136.</Citation></Reference><Reference><Citation>Coulson JM, Adams A, Gray LA, Evans A. COVID-19 &#x201c;rebound&#x201d; associated with nirmatrelvir/ritonavir pre-hospital therapy. J Infect. 2022;85(4):436-480.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>